Retatrutide: the TRIUMPH-1 results that reshaped metabolic research talk

In May 2026, Eli Lilly announced positive TRIUMPH-1 Phase 3 topline results for retatrutide — an investigational GIP, GLP-1 and glucagon triple agonist — in adults with obesity or overweight plus at least one weight-related comorbidity, without diabetes.

Under the reported efficacy estimand, participants on the highest studied dose (12 mg) achieved an average 28.3% weight reduction at 80 weeks — about 70.3 lb from a ~248.5 lb baseline. In that arm, 45.3% achieved ≥30% weight reduction.

The company also reported that 65.3% of participants on 12 mg moved from BMI ≥30 to BMI <30 by week 80. In a pre-specified extension for BMI ≥35, those continuing 12 mg to 104 weeks averaged about 30.3% weight reduction.

Beyond weight, the release cited improvements in observed cardiometabolic risk markers. That is why retatrutide is widely discussed in contemporary metabolic research — still as an investigational molecule.

For readers in Asunción, Paraguay, the takeaway is scientific context from controlled trials — not a commercial miracle claim.

At EDGE VITAL, RETATRUTIDE+ 60mg is part of the premium catalog with declared 99% purity, American technology and cold chain. Check availability in Asunción with Eduardo.